Five Health Tech Developments: Continued Profits and Pressure for PBMs

As the lack of transparency from PBMs continues to generate debate, the call for reform has never been louder. Our CEO, Chris Blackley, spoke with Forbes about drug pricing and how PBM reform is the first step in enacting change: “Ultimately, promoting competition in the PBM market could be the ‘cure’ for the systemic issues plaguing drug pricing,” he said. See the full story on Forbes.com.